Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerard Morton

Showing results (101-110 of 122) with videos related to

Pageof 13
Sort By:
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|July 20, 2020
Radiation Oncology Fellowship: a Value-Based Assessment Among Graduates of a Mature ProgramEmma Ito, Fabio Y Moraes, Matthew Ramotar, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 6, 2021
Elective nodal ultra hypofractionated radiation for prostate cancer: Safety and efficacy from four prospective clinical trialsRachel M Glicksman, Stanley K Liu, Patrick Cheung, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 12, 2020
Single-fraction HDR brachytherapy as monotherapy in low and intermediate risk prostate cancer: Outcomes from two clinical trials with and without an MRI-guided boostYasir Alayed, Andrew Loblaw, Merrylee McGuffin, et al.
Brachytherapy|July 24, 2025
High-dose-rate (HDR) brachytherapy boost in combination with external beam radiotherapy for localized prostate cancer: An evidence-based consensus statementSagar A Patel, Marisa Kollmeier, Juanita Crook, et al.
Clinical and Translational Radiation Oncology|November 29, 2021
Defining radio-recurrent intra-prostatic target volumes using PSMA-targeted PET/CT and multi-parametric MRIWei Liu, Hatim Fakir, Gurpreet Randhawa, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 13, 2022
Two-fraction stereotactic ablative radiotherapy (SABR) versus two-fraction high dose rate (HDR) brachytherapy for localized prostate cancer: Does dose heterogeneity matter?Rohann J M Correa, Gerard Morton, Hans T Chung, et al.
International Journal of Radiation Oncology, Biology, Physics|October 13, 2018
A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer After External Beam Radiation Therapy (NRG Oncology/RTOG-0526)Juanita M Crook, Peixin Zhang, Thomas M Pisansky, et al.
International Journal of Radiation Oncology, Biology, Physics|July 7, 2023
To Boost or Not to Boost: Pooled Analyses From 2-Fraction SABR Trials for Localized Prostate CancerWee Loon Ong, Patrick Cheung, Hans Chung, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 24, 2023
Dosimetric correlates of toxicities and quality of life following two-fraction stereotactic ablative radiotherapy (SABR) for prostate cancerWee Loon Ong, Melanie Davidson, Patrick Cheung, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 8, 2023
Two-fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intra-prostatic lesion - Results from the 2SMART phase 2 trialWee Loon Ong, Patrick Cheung, Hans Chung, et al.
Pageof 13

Showing results (101-110 of 122) with videos related to

Sort By:
Pageof 13
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|July 20, 2020
Radiation Oncology Fellowship: a Value-Based Assessment Among Graduates of a Mature ProgramEmma Ito, Fabio Y Moraes, Matthew Ramotar, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 6, 2021
Elective nodal ultra hypofractionated radiation for prostate cancer: Safety and efficacy from four prospective clinical trialsRachel M Glicksman, Stanley K Liu, Patrick Cheung, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 12, 2020
Single-fraction HDR brachytherapy as monotherapy in low and intermediate risk prostate cancer: Outcomes from two clinical trials with and without an MRI-guided boostYasir Alayed, Andrew Loblaw, Merrylee McGuffin, et al.
Brachytherapy|July 24, 2025
High-dose-rate (HDR) brachytherapy boost in combination with external beam radiotherapy for localized prostate cancer: An evidence-based consensus statementSagar A Patel, Marisa Kollmeier, Juanita Crook, et al.
Clinical and Translational Radiation Oncology|November 29, 2021
Defining radio-recurrent intra-prostatic target volumes using PSMA-targeted PET/CT and multi-parametric MRIWei Liu, Hatim Fakir, Gurpreet Randhawa, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 13, 2022
Two-fraction stereotactic ablative radiotherapy (SABR) versus two-fraction high dose rate (HDR) brachytherapy for localized prostate cancer: Does dose heterogeneity matter?Rohann J M Correa, Gerard Morton, Hans T Chung, et al.
International Journal of Radiation Oncology, Biology, Physics|October 13, 2018
A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer After External Beam Radiation Therapy (NRG Oncology/RTOG-0526)Juanita M Crook, Peixin Zhang, Thomas M Pisansky, et al.
International Journal of Radiation Oncology, Biology, Physics|July 7, 2023
To Boost or Not to Boost: Pooled Analyses From 2-Fraction SABR Trials for Localized Prostate CancerWee Loon Ong, Patrick Cheung, Hans Chung, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 24, 2023
Dosimetric correlates of toxicities and quality of life following two-fraction stereotactic ablative radiotherapy (SABR) for prostate cancerWee Loon Ong, Melanie Davidson, Patrick Cheung, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|February 8, 2023
Two-fraction stereotactic ablative radiotherapy with simultaneous boost to MRI-defined dominant intra-prostatic lesion - Results from the 2SMART phase 2 trialWee Loon Ong, Patrick Cheung, Hans Chung, et al.
Pageof 13